Yu SJ, Yu JK, Ge WT, Hu HG, Yuan Y, Zheng S. SPARCL1, Shp2, MSH2, E-cadherin, p53, ADCY-2 and MAPK are prognosis-related in colorectal cancer. World J Gastroenterol 2011; 17(15): 2028-2036 [PMID: 21528083 DOI: 10.3748/wjg.v17.i15.2028]
Corresponding Author of This Article
Shu Zheng, Professer, Cancer Institute, the Second Affiliated Hospital, Zhejiang University College of Medicine, 88 Jiefang Road, Hangzhou 310009, Zhejiang Province, China. zhengshu@zju.edu.cn
Article-Type of This Article
Brief Article
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Shu-Jing Yu, Department of Radiation Oncology (Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education, Key Laboratory of Molecular Biology in Medical Science, Zhejiang Province, China), the Second Affiliated Hospital, Zhejiang University College of Medicine, Hangzhou 310009, Zhejiang Province, China
Jie-Kai Yu, Wei-Ting Ge, Shu Zheng, Cancer Institute (Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education, Key Laboratory of Molecular Biology in Medical Science, Zhejiang Province, China), the Second Affiliated Hospital, Zhejiang University College of Medicine, Hangzhou 310009, Zhejiang Province, China
Han-Guang Hu, Ying Yuan, Department of Medical Oncology, the Second Affiliated Hospital, Zhejiang University College of Medicine, Hangzhou 310009, Zhejiang Province, China
Author contributions: Yu SJ performed the majority of experiments and wrote the manuscript; Yu JK performed the bioinformatics analyses and was also involved in editing the manuscript; Ge WT was involved in editing the manuscript and analyzing experiment data; Yuan Y and Hu HG provided the collection of all the human material; Zheng S designed the study and edited the manuscript.
Supported by Grants from the Major State Basic Research Development Program of China, 973 Program No. 2004CB518707; the Zhejiang Provincial Natural Science Foundation of China, No. R2090353; the Fundamental Research Funds for the Central Universities, No. KYJD09007
Correspondence to: Shu Zheng, Professer, Cancer Institute, the Second Affiliated Hospital, Zhejiang University College of Medicine, 88 Jiefang Road, Hangzhou 310009, Zhejiang Province, China. zhengshu@zju.edu.cn
Telephone: +86-571-87784501 Fax: +86-571-87214404
Received: November 10, 2010 Revised: December 17, 2010 Accepted: December 24, 2010 Published online: April 21, 2011
Abstract
AIM: To investigate the expression of markers that are correlated with the prognosis of colorectal cancer (CRC) patients.
METHODS: One hundred and fifty-six CRC patients were followed up for more than 3 years after radical surgery. Immunohistochemical (IHC) analysis was performed to detect the expression of 14 pathway-related markers (p53, APC, p21ras, E-cadherin, endothelin-B receptor, Shp2, ADCY-2, SPARCL1, neuroligin1, hsp27, mmp-9, MAPK, MSH2 and rho) in specimens from these patients. Bioinformatics analysis involving a Support Vector Machine (SVM) was used to determine the best prognostic model from combinations of these markers.
RESULTS: Seven markers (SPARCL1, Shp2, MSH2, E-cadherin, p53, ADCY-2 and MAPK) were significantly related to the prognosis and clinical pathological features of the CRC patients (P < 0.05). Prognostic models were established through SVM from combinations of these 7 markers and proved able to differentiate patients with dissimilar survival, especially in stage II/III patients. According to the best prognostic model, the p53/SPARCL1 model, patients having high p53 and low SPARCL1 expression had about 50% lower 3-year survival than others (P < 0.001).
CONCLUSION: SPARCL1, Shp2, MSH2, E-cadherin, p53, ADCY-2 and MAPK are potential prognostic markers in CRC. A p53/SPARCL1 bioinformatics model may be used as a supplement to tumor-nodes-metastasis staging.
